5.13. MOLECULAR METHODS
421
The early appearance of breast cancer (at a mean age of 37 years) is
highly associated with p53 mutations. Fifty per cent of Li–Fraumeni syndrome
cases, a predominantly inherited syndrome associated with multiple primary
neoplasms of children and young adults, have a germ line p53 mutation and
49% of families with germ line p53 mutations meet the criteria for Li–Fraumeni
syndrome: occurrence of sarcoma before 45 years of age and at least one first
degree relative with a tumour before 45 years of age or a sarcoma at any age.
Inherited germ line p53 mutations are associated with breast cancer
(24%), bone sarcomas (13%), brain tumours (12%) and soft tissue sarcomas
(12%). Adrenocortical carcinoma is not common (4%) but in children is
almost always associated with a germ line p53 mutation.
Another interesting feature is found in some geographical areas where an
overlapping of hepatitis B infection and exposure to the mould toxin (aflatoxin
B) leads to mutation in the p53 gene. This can be reflected in the future
appearance of an aggressive hepatocellular carcinoma.
The p53 gene can be considered a prognostic marker for several tumours.
In colorectal carcinoma p53 mutations are present in 75% of cases. In lymph
node negative breast cancer the 8 year survival rate in p53 negative women is
82%, whereas in p53 positive cases it is 66%. Furthermore, in lymph node
positive cases, p53 positive cases are associated with a 20% 8 year survival rate
and p53 negative cases present a 56% survival, leading to the conclusion that
the presence of mutations in the gene corresponds to a poor overall survival. In
prostate cancer, p53 is considered to be a marker of tumour progression. In
lymphoma, the survival is lower in patients bearing mutations in the p53 gene
than in those patients with wild type p53. Considering colorectal carcinoma, the
5 year survival rate in p53 positive patients is 18% lower than that of p53
negative patients.
Aggressive myeloid chronic leukaemia presents mutations in p53 in 29–
50% of cases. These values contrast to those found in typical cases (6–9%).
Furthermore, the survival time in p53 positive patients with that kind of
leukaemia is 12–18 months, while in p53 negative patients the survival period
extends to 60–117 months.
Resistance to a specific therapeutic scheme can also be affected by
mutations in the p53 gene. In breast cancer, p53 mutations increase resistance
of tumours to ionizing radiation. In B cell chronic leukaemia, the mutations in
the gene are translated as a resistance to chemotherapy. The same
phenomenon is observed in ovarian cancer, where wild type p53 tumours are
more sensitive to chemotherapy.